» Articles » PMID: 22156981

Outcomes of the Bowel Cancer Screening Programme (BCSP) in England After the First 1 Million Tests

Overview
Journal Gut
Specialty Gastroenterology
Date 2011 Dec 14
PMID 22156981
Citations 194
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The Bowel Cancer Screening Programme in England began operating in 2006 with the aim of full roll out across England by December 2009. Subjects aged 60-69 are being invited to complete three guaiac faecal occult blood tests (6 windows) every 2 years. The programme aims to reduce mortality from colorectal cancer by 16% in those invited for screening.

Methods: All subjects eligible for screening in the National Health Service in England are included on one database, which is populated from National Health Service registration data covering about 98% of the population of England. This analysis is only of subjects invited to participate in the first (prevalent) round of screening.

Results: By October 2008 almost 2.1 million had been invited to participate, with tests being returned by 49.6% of men and 54.4% of women invited. Uptake ranged between 55-60% across the four provincial hubs which administer the programme but was lower in the London hub (40%). Of the 1.08 million returning tests 2.5% of men and 1.5% of women had an abnormal test. 17,518 (10,608 M, 6910 F) underwent investigation, with 98% having a colonoscopy as their first investigation. Cancer (n=1772) and higher risk adenomas (n=6543) were found in 11.6% and 43% of men and 7.8% and 29% of women investigated, respectively. 71% of cancers were 'early' (10% polyp cancer, 32% Dukes A, 30% Dukes B) and 77% were left-sided (29% rectal, 45% sigmoid) with only 14% being right-sided compared with expected figures of 67% and 24% for left and right side from UK cancer registration.

Conclusion: In this first round of screening in England uptake and fecal occult blood test positivity was in line with that from the pilot and the original European trials. Although there was the expected improvement in cancer stage at diagnosis, the proportion with left-sided cancers was higher than expected.

Citing Articles

Genetics, primary care records and lifestyle factors for short-term dynamic risk prediction of colorectal cancer: prospective study of asymptomatic and symptomatic UK Biobank participants.

Ip S, Harrison H, Usher-Smith J, Barclay M, Tyrer J, Dennis J BMJ Oncol. 2025; 4(1):e000336.

PMID: 40046831 PMC: 11880779. DOI: 10.1136/bmjonc-2024-000336.


Inequalities in colorectal cancer diagnosis by ethnic group: a population-level study in the English National Health Service.

Birch R, Burr N, Taylor J, Downing A, Quirke P, Morris E BMJ Open Gastroenterol. 2025; 12(1).

PMID: 39778976 PMC: 11749721. DOI: 10.1136/bmjgast-2024-001629.


COLOFIT: Development and Internal-External Validation of Models Using Age, Sex, Faecal Immunochemical and Blood Tests to Optimise Diagnosis of Colorectal Cancer in Symptomatic Patients.

Crooks C, West J, Jones J, Hamilton W, Bailey S, Abel G Aliment Pharmacol Ther. 2025; 61(5):852-864.

PMID: 39764729 PMC: 11825929. DOI: 10.1111/apt.18459.


Asymptomatic Inflammatory Bowel Disease Diagnosed During Colorectal Cancer Population Screening in Catalonia: Characteristics and Natural History.

Brunet-Mas E, Selva A, Bas-Cutrina F, Brujats A, Caballol B, Font R Clin Transl Gastroenterol. 2024; 16(2):e00740.

PMID: 39729123 PMC: 11845185. DOI: 10.14309/ctg.0000000000000740.


Significant variation in the assessment and management of screen-detected colorectal polyp cancers.

Hallam S, Farrugia A, Naumann D, Trudgill N, Rout S, Karandikar S Int J Colorectal Dis. 2024; 39(1):209.

PMID: 39710791 PMC: 11663814. DOI: 10.1007/s00384-024-04780-y.


References
1.
Benson V, Patnick J, Davies A, Nadel M, Smith R, Atkin W . Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2007; 122(6):1357-67. DOI: 10.1002/ijc.23273. View

2.
Hewitson P, Glasziou P, Watson E, Towler B, Irwig L . Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008; 103(6):1541-9. DOI: 10.1111/j.1572-0241.2008.01875.x. View

3.
Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H, Karnon J . Option appraisal of population-based colorectal cancer screening programmes in England. Gut. 2006; 56(5):677-84. PMC: 1942136. DOI: 10.1136/gut.2006.095109. View

4.
Lee T, Rutter M, Blanks R, Moss S, Goddard A, Chilton A . Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme. Gut. 2011; 61(7):1050-7. DOI: 10.1136/gutjnl-2011-300651. View

5.
Eilbert K, Carroll K, Peach J, Khatoon S, Basnett I, McCulloch N . Approaches to improving breast screening uptake: evidence and experience from Tower Hamlets. Br J Cancer. 2009; 101 Suppl 2:S64-7. PMC: 2790710. DOI: 10.1038/sj.bjc.6605393. View